Combretastatin A-4 and its analogs in cancer therapy

Document Type

Article

Publication Date

9-1-2013

Abstract

Combretastatin A-4 (CA-4) is an anti-mitotic agent that is gaining rapid recognition among cancer biologists and clinicians as one of the newer vascular disrupting agents, (VDAs) for cancer therapy. CA-4 belongs to a group of tubulin binding natural products called combretastatin, derived from the African Bush Willow, Combretum caffrum. Due to CA-4′s in vivo efficacy, a number of analogs of CA-4 have been synthesized to maximize its solubility and bioavailability. Combretastatin A-4 phosphate is a more soluble form of CA-4 that has successfully completed phase I trial and is currently under phase II/III trials for treatment of acute myelogenous leukemia and relapsed ovarian cancer. This review attempts to highlight the various CA-4 analogs that have been synthesized and their effectiveness in clinical trials as VDAs.

Publication Title

International Journal of Pharmaceutical Sciences Review and Research

First Page Number

168

Last Page Number

174

This document is currently not available here.

Share

COinS